Insmed Stock Skyrockets on Breakthrough Lung Disease Drug Success
TL;DR Summary
Insmed's stock surged 135% after announcing successful Phase 3 trial results for brensocatib in treating non-cystic fibrosis bronchiectasis, showing significant reductions in pulmonary exacerbations. The company plans to file for FDA approval in late 2024, with potential U.S. launch in mid-2025 and subsequent launches in Europe and Japan.
Topics:business#brensocatib#businesshealthcare#insmed#non-cystic-fibrosis-bronchiectasis#phase-3-study#stock-surge
- Why Is Inflammatory Diseased-Focused Insmed Stock Soaring On Tuesday? Yahoo Finance
- Insmed Stock Surges on Trial Win for Lung-Condition Drug, a Possible Blockbuster Barron's
- Insmed CEO on lung disease treatment and path forward CNBC
- Insmed's shares double as lung disease med powers past expectations in phase 3 Fierce Biotech
- Insmed Stock Catapults On Its Humira-Like Potential In Lung Disease Investor's Business Daily
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
1 min
vs 2 min read
Condensed
85%
318 → 48 words
Want the full story? Read the original article
Read on Yahoo Finance